Document is current
Any future updates will be listed below
-
Authors
Mattsson, Niklas https://orcid.org/0000-0002-8885-7724
Insel, Philip S
Palmqvist, Sebastian
Portelius, Erik
Zetterberg, Henrik
Weiner, Michael
Blennow, Kaj
Hansson, Oskar
,
-
Funding
Funding for this research was provided by:
Alzheimer's Disease Neuroimaging Initiative
Biogen Idec Inc.
Bristol‐Myers Squibb Company
Eisai Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
Genentech, Inc.
Fujirebio
IXICO Ltd.
Janssen Research & Development
National Institutes of Health (U01 AG024904)
Johnson & Johnson
Medpace, Inc.
Merck & Co., Inc.
Meso Scale Diagnostics, LLC.
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
U.S. Department of Defense (W81XWH‐12‐2‐0012)
Pfizer Inc.
Piramal Imaging
Servier
Synarc Inc.
Takeda Pharmaceutical Company
Canadian Institutes of Health Research
Foundation for the National Institutes of Health
Northern California Institute for Research and Education
European Research Council
Swedish Research Council
Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
Swedish Brain Foundation
Skåne University Hospital Foundation
National Institute on Aging
Swedish Alzheimer Association
Stiftelsen för Gamla Tjänarinnor
Thelma Zoéga Foundation
Greta and Johan Kock Foundation
Magnus Bergvwall Foundation
Knut and Alice Wallenberg Foundation
Torsten Söderberg Foundation
National Institute of Biomedical Imaging and Bioengineering
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
F. Hoffmann‐La Roche Ltd
GE Healthcare
- License Information
-
More Information
Article History
Received: 25 April 2016
Revised: 22 June 2016
Accepted: 8 July 2016
First Online: 17 August 2016
Conflict of interest
: NM, SP, EP, and OH declare that they have no conflict of interest. HZ and KB are co‐founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture‐based platform company at the University of Gothenburg. MW has served on the Scientific Advisory Boards for Pfizer, Alzheon, Inc., Eli Lilly; has provided consulting to Synarc, Pfizer, Janssen, Alzheimer's Drug Discovery Foundation (ADDF), Avid Radiopharmaceuticals, Araclon, Merck, Biogen Idec, BioClinica, and Genentech; holds stock options with Alzheon, Inc; and has received funding for academic travel from Pfizer, Kenes, Intl., UCSD; ADCS, University Center Hospital, Toulouse, Araclon, AC Immune, Nutricia, Eli Lilly, New York Academy of Sciences (NYAS), The Alzheimer's Association, Merck, Alzheimer's Drug Discovery Foundation (ADDF), Tokyo University, Kyoto University, Weill‐Cornell University, Rockafeller University, Memorial Sloan‐Kettering Cancer Center, and Biogen Idec.
